Interfering with the intracellular levels of cyclic adenosine monophosphate (cAMP) was proposed almost two decades ago as a promising target.
CYCLIC ADENOSINE MONOPHOSPHATE (CAMP)
cAMP is a key intracellular second messenger ( Fig. 1 ) [1] . cAMP signalling is activated by a variety of G protein-coupled receptor ligands. The cAMP system is also involved in a variety of epithelial functions and plays a role in maintenance of the skin barrier. In the keratinocyte cell line HaCat largely suppressed chemokine production (CXCL10, CCL17, and CCL22) has been described [26, 27] in the context of increased cAMP levels.
PHOSPHODIESTERASE 4 (PDE4)
There are several PDE families, all isoforms of which are concerned with the intracellular degradation of the phosphodiesterase bonds of cAMP and cyclic guanosine monophosphate [29] , and for respiratory diseases by Page and Spina [30] . In immune cells, the isoforms PDE4A, B and D (but not C) are highly expressed as well as PDE3 and 7 [30] . It is noteworthy, however, that the activity of macrophages may not be significantly inhibited by PDE4 selective inhibitors [31] . The benefit of a combined effect of PDE7 or PDE3 with PDE4 selective inhibitors on macrophage and T cell function has been described [32, 33] .
The expression levels of these PDE isoenzymes are regulated by a variety of stimuli. For example, prostaglandin E2 induces PDE3 and 4 activity and PDE3B, 4A4, 4A1, 4D2 and 4D3 expression [34] . T cell receptor stimulation increases the differential expression of PDE4 subtypes in cluster of differentiation 4 (CD4?T) cells [35] , and tolllike receptor 4 (TLR4) stimulation acts on PDE4B2 expression in human monocytes [36] .
PDE INHIBITORS

Non-Selective PDE Inhibitors
Pentoxifylline is a competitive non-selective PDE inhibitor (used in the treatment of peripheral vascular disease) which raises intracellular cAMP levels to inhibit TNF and reduce inflammation. Pentoxifylline is also an adenosine 2 receptor antagonist. It reduces blood viscosity and platelet aggregation. Although suggested by some authors, pentoxifylline is not effective on the activity of psoriasis [37] . Some beneficial effect has been reported in canine atopic dermatitis [38] and human lung sarcoidosis [39] .
Theophylline inhibits to some extent PDE1-5 (least effective against PDE4; [40] ), is a potent adenosine receptor antagonist and an activator of histone deacetylase 2 (HDAC2) such that it might exert beneficial effects on (allergic) lung inflammation [41] . inhibition have been studied extensively in the treatment of COPD and asthma [46, 47] .
Recent human clinical data on PDE4 inhibitors on skin diseases and in particular on psoriasis are available for apremilast. Apremilast is an orally available PDE4 inhibitor [48] which does not show any marked selectivity among the PDE4 isotypes. It seems to elicit less emetic side effects while also having a wide therapeutic inhibition of TNF production in murine monocyte/macrophages [51, 52] . Apremilast has inhibitory activity on TNFa release by ultraviolet B (UVB) activated (50 mJ/cm 2 )
keratinocytes [53] .
PDE4 Inhibitors in Dermatologic Diseases
Data suggest a promising therapeutic effect for selective PDE4 inhibitors on inflammatory skin diseases [54] . Of note, a PDE7A inhibitor was also successful in suppressing dermatitis and TNF expression in mice studies [55] . In One study points to a potentially beneficial effect of apremilast in cutaneous sarcoidosis [56] and it will be interesting to further explore the activity of PDE4 inhibitors in 
CLINICAL STUDIES IN PSORIATIC ARTHRITIS
In psoriatic arthritis there is only one published study of the efficacy of apremilast-a phase 2 randomized placebo controlled study [71] . The
Dermatol Ther (Heidelb) (2013) 3:1- 15 7 results of the phase 3 PALACE-I study were presented at the American College of Rheumatology (ACR) meeting in Washington DC in November 2012 [72] .
The phase II study enrolled 204 patients with active psoriatic arthritis, defined by more than or equal to 3 tender and 3 swollen joints. Only co-prescription with a stable dose of methotrexate or oral glucocorticoids was allowed: all other disease modifying drugs had to be discontinued before enrolment. The usual restrictions on major co-morbid conditions applied. Patients were randomized equally to placebo, apremilast 20 mg bd or apremilast 40 mg once daily (od), stratified by baseline methotrexate use. After 12 weeks of treatment patients could stop treatment or enter a further 12 week extension phase, the latter option occurring as an amendment to the original protocol design, and re-randomisation of placebo to one of the active treatment groups.
The primary efficacy endpoint was the proportion of patients achieving a modified (by joint count) ACR 20% improvement at 12 weeks (ACR20). The primary endpoint was achieved by 43.5% of patients in the apremilast 20 mg bd group, 35.8% of patients in the 40 mg od group, and 11.8% of patients on placebo, the differences between active drug and placebo being highly significant (see Table 1 ) [71, 72] . In the extension phase, where patients who had initially taken placebo were transferred to an active drug, a similar improvement was seen in the people who transferred, and the initial improvements in the active treatment groups were maintained. Stratified for methotrexate use there was no difference in primary outcome between the two groups, although more people on combination had gastro-intestinal side effects. No assessments of skin, enthesitis, dactylitis, or axial involvement were made in this study. Overall safety data were good with diarrhoea and headache being the major, albeit no more than moderate, side effects. Abnormal laboratory results, including liver enzyme elevations, were infrequent.
The PALACE-I study has only been reported in abstract form [72] . This study enrolled 504 patients with active psoriatic arthritis (more than three tender and swollen joints) who were randomized in an equal ratio to placebo, apremilast 20 mg bd and apremilast 30 mg bd. The patients were stratified by previous disease modifying drug use and about three quarters were TNF inhibitor naive. The primary outcome measure was again the ACR20 at 16 weeks which was achieved by 19.4%, 31.3%, and 41% of the placebo, 20 and 30 mg bd groups, respectively. At 24 weeks the corresponding figures for per protocol treatment (i.e. those All figures are percentages D1 for phase 2 and phase 3 was 20 mg twice daily (bd) D2 for phase 2 was 40 mg once daily (od), for phase 3 was 30 mg bd [71, 72] still taking placebo) were ACR20 of 13%, 36%, and 45%. Patients on placebo had the chance to re-randomise to active drug at 16 weeks and a long-term extension for all patients is underway. As expected, patients who had previously taken biologics had less impressive responses, the ACR20 rates for the 20 and 30 mg bd groups at 16 weeks being 31% and 28%, respectively. Those taking disease modifying drugs (mostly methotrexate) had rather blunted responses (ACR20 rates of 31%
and 35% for 20 and 30 mg bd, respectively).
Skin responses were also reported: in patients with a skin surface area of greater than 3% at baseline the PASI75 rates at week 24 were 5%, 18% and 21% for placebo, 20 mg bd and 30 mg bd, respectively. Serious adverse events were rare and, again, adverse events were mainly gastrointestinal (diarrhoea and nausea) and headache, but a small increase in upper respiratory infections was also seen [72] . TNFi. Apremilast appears to have a good safety profile and this, together with the oral dosing are likely to be major factors in the decision to use the drug. However, much will depend on the cost and long-term tolerability and safety.
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